Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Common Equity (2020 - 2025)

Barinthus Biotherapeutics' Common Equity history spans 6 years, with the latest figure at $74.2 million for Q4 2025.

  • For Q4 2025, Common Equity fell 42.98% year-over-year to $74.2 million; the TTM value through Dec 2025 reached $74.2 million, down 42.98%, while the annual FY2025 figure was $74.2 million, 42.98% down from the prior year.
  • Common Equity reached $74.2 million in Q4 2025 per BRNS's latest filing, down from $84.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $254.8 million in Q2 2022 to a low of -$52.8 million in Q1 2021.
  • Average Common Equity over 5 years is $175.8 million, with a median of $191.3 million recorded in 2023.
  • The largest YoY upside for Common Equity was 954.6% in 2021 against a maximum downside of 104.32% in 2021.
  • A 5-year view of Common Equity shows it stood at $252.6 million in 2021, then fell by 3.71% to $243.2 million in 2022, then dropped by 23.11% to $187.0 million in 2023, then plummeted by 30.41% to $130.1 million in 2024, then crashed by 42.98% to $74.2 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Common Equity are $74.2 million (Q4 2025), $84.5 million (Q3 2025), and $102.5 million (Q2 2025).